Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Profound Medical Corp T.PRN

Alternate Symbol(s):  PROF

Profound Medical Corp. is a Canada-based commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue. It is commercializing TULSA-PRO, a technology that combines real-time magnetic resonance imaging (MRI), robotically driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA procedure, performed using the TULSA-PRO system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low -, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (BPH); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. It is also commercializing Sonalleve, a therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases.


TSX:PRN - Post by User

Comment by HomerAndCompanyon Oct 05, 2021 9:46am
122 Views
Post# 33966340

RE:RE:RE:RE:Target 25 installations by YE, up from 14 as of Q2 Conf Call

RE:RE:RE:RE:Target 25 installations by YE, up from 14 as of Q2 Conf Call
MrMugsy wrote:
HomerAndCompany wrote:
MrMugsy wrote:
HomerAndCompany wrote:
This increase in the rate of installations is to be facilitated by doubling the size of sales and installation teams by Q4. .


Not sure I understand the numbers ...
- 11 Procedure Centers in USA (one of them doubles as a learning center)
- 1 additional learning center
- 7 in Europe
- 1 in Japan
That's 20 in total

Are they going to 25 in total (5 more)   - OR -   25 in the USA for 2021 ?

Not much time in 2021 if they plan on getting to 25 in the USA alone - unless they're adding but not updating the company map at this time. I


 


My understanding from the Q2 conference call was that they had 14 sites giving treatments at that time, with a target of 25 sites giving treatments by the end of 2021. Not all of the 20 sites you list are giving treatments, as you identifed one as a learning site only.
I'd have to listen to the Q2 call again to try to reconcile the numbers. But more important than the specific numbers is the intention to significantly accerlerate the rate at which new sites are added by doubling their sales and installation teams by Q3.


Thanks - I will have a closer listen.  I've heard so many numbers thrown around  that I'm now questioning  what the actual goal is by yearend.  Thanks.


What seemed clear moreso than the exact numbers is that PRN views the past financial progress as slow (the consequence of a conservative approach taken with early installations they say)
and expects that progress to speed up through a number of actions they are taking in Q4 and 2021, as well as the snowballing effect from existing installations ramping up.
<< Previous
Bullboard Posts
Next >>